ClinicalTrials.gg

Program

SPG-302

Also written as “SPG302” and “Tazbentetol”.

Its studies are mostly in Amyotrophic Lateral Sclerosis · Alzheimer Disease · Schizophrenia, led by Spinogenix.

Furthest: phase 3, since Jan 6, 20266 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Spinogenix63 open or runningphase 3since Jan 6, 2026May 22, 2023Dec 31, 2027phase 3 · NCT07325591

Also a collaborator on its studies: novotech-australia-pty-limited.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 22, 2023First study: phase 1 study in Amyotrophic Lateral SclerosisFirst studyNCT05882695 · 88 enrolled · Australia
  2. May 13, 20242 phase 2 studiesNCT06427668, NCT06442462
  3. Feb 12, 2025Phase 2 study in Alzheimer DiseaseNCT06833281 · 12 enrolled · Australia
  4. Mar 24, 2025Phase 2 study in Amyotrophic Lateral SclerosisNCT06903286 · 16 enrolled · Australia
  5. Jan 6, 2026Phase 3 study in Amyotrophic Lateral SclerosisPhase 3 reachedNCT07325591 · 430 planned

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in Amyotrophic Lateral SclerosisNCT07325591

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07325591Amyotrophic Lateral Sclerosis3Not yet recruitingDec 31, 2027430
NCT06903286Amyotrophic Lateral Sclerosis · Australia2TerminatedJun 30, 202516
NCT06833281Alzheimer Disease · Australia2TerminatedJul 30, 202512
NCT06442462Schizophrenia · United States, Australia2Active, not recruitingMar 202632
NCT06427668Alzheimer Disease · Australia2Active, not recruitingDec 202524
NCT05882695Amyotrophic Lateral Sclerosis · Australia1CompletedJun 27, 202588

How it is read

Names in the registry

  • “SPG302”, 5 entries
  • “Tazbentetol”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.